SCHEMBL6360772

SCHEMBL6360772

Clc1cncc(N2CCCNCC2)n1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.87
HTR2A P28223 2/20 0.87
HTR2C P28335 2/20 0.87
KDM4E B2RXH2 1/20 0.87
MEN1 O00255 1/20 0.87
CYP1A2 P05177 1/20 0.87
CYP3A4 P08684 1/20 0.87
HTR1A P08908 1/20 0.87
CYP2C9 P11712 1/20 0.87
HPGD P15428 1/20 0.87
CYP2C19 P33261 1/20 0.87
KMT2A Q03164 1/20 0.87
HSD17B10 Q99714 1/20 0.87
CHRNB2 P17787 8/20 0.55
CHRNA4 P43681 8/20 0.55
CHRNA1 P02708 1/20 0.55
CHRNA7 P36544 1/20 0.55
HTR3E A5X5Y0 1/20 0.53
HTR3B O95264 1/20 0.53
HTR3A P46098 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mk-212 SCHEMBL29389957 0.93 HTR2A (1.00) ALDH1A1HTR2AHTR2CKDM4EMEN1
Mk-212 SCHEMBL255453 0.93 HTR2A (1.00) ALDH1A1HTR2AHTR2CKDM4EMEN1
Mk-212 SCHEMBL3060615 0.92 HTR2A (0.96) ALDH1A1HTR2AHTR2CKDM4EMEN1
Mk-212 SCHEMBL12503246 0.90 HTR2A (0.93) ALDH1A1HTR2AHTR2CKDM4EMEN1
SCHEMBL939716 0.84 ALDH1A1 (0.70) ALDH1A1HTR2AHTR2CKDM4EMEN1
SCHEMBL31558499 0.83 CYP1A2 (0.68) ALDH1A1HTR2AHTR2CKDM4EMEN1
SCHEMBL19673985 0.83 CYP1A2 (0.68) ALDH1A1HTR2AHTR2CKDM4EMEN1
SCHEMBL2007079 0.81 KDM4E (0.57) ALDH1A1HTR2AHTR2CKDM4EMEN1
Mk-212 SCHEMBL4420315 0.80 HTR2A (0.73) ALDH1A1HTR2AHTR2CKDM4EMEN1
Mk-212 SCHEMBL27809059 0.77 HTR2C (0.68) ALDH1A1HTR2AHTR2CKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US claimed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 EP claimed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US claimed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 EP claimed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 WO claimed
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 EP disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
CN-1131211-C Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2003-12-17 CN disclosed
CN-1277604-A Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2000-12-20 CN disclosed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 EP disclosed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 ALDH1A1 2299/4885HTR2A 2094/4885HTR2C 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.